Inclusion of Safety-Related Issues in Economic Evaluations for Seasonal Influenza Vaccines: A Systematic Review
Open Access
- 1 February 2021
- Vol. 9 (2), 111
- https://doi.org/10.3390/vaccines9020111
Abstract
(1) Background: Vaccines for seasonal influenza are a good preventive and cost-effective strategy. However, it is unknown if and how these economic evaluations include the adverse events following immunization (AEFI), and what the impact of such inclusion is on the health economic outcomes. (2) Methods: We searched the literature, up to January 2020, to identify economic evaluations of seasonal influenza vaccines that considered AEFIs. The review protocol was published in PROSPERO (CDR42017058523). (3) Results: A total of 52 economic evaluations considered AEFI-related parameters in their analyses, reflecting 16% of the economic evaluations on seasonal influenza vaccines in the initial study selection. Most studies used the societal perspective (64%) and evaluated vaccination of children (37%). Where considered, studies included direct medical costs of AEFIs (90%), indirect costs (27%), and disutilities/quality-adjusted life years loss due to AEFIs (37%). The majority of these studies accounted for the effects of the costs of AEFI on cost-effectiveness for Guillain–Barré syndrome. In those papers allowing cost share estimation, direct medical cost of AFEIs was less than 2% of total direct costs. (4) Conclusions: Although the overall impact of AEFIs on the cost-effectiveness outcomes was found to be low, we urge their inclusion in economic evaluations of seasonal influenza vaccines to reflect comprehensive reports for the decision makers and end-users of the vaccination strategies.This publication has 92 references indexed in Scilit:
- Ontology-Based Combinatorial Comparative Analysis of Adverse Events Associated with Killed and Live Influenza VaccinesPLOS ONE, 2012
- The potential economic value of a ‘universal’ (multi‐year) influenza vaccineInfluenza and Other Respiratory Viruses, 2011
- Cost-Effectiveness of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Adult Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2011
- From the patient perspective: The economic value of seasonal and H1N1 influenza vaccinationVaccine, 2011
- Cost-effectiveness of dual influenza and pneumococcal vaccination in 50-year-oldsVaccine, 2010
- Economics of employer-sponsored workplace vaccination to prevent pandemic and seasonal influenzaVaccine, 2010
- Economic Value of Seasonal and Pandemic Influenza Vaccination during PregnancyClinical Infectious Diseases, 2009
- The timing of influenza vaccination for older adults (65 years and older)Vaccine, 2009
- A predictive model of the economic effects of an influenza vaccine adjuvant for the older adult (age 65 and over) populationVaccine, 2009